within Pharmacolibrary.Drugs.ATC.R;

model R03DA55
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 4.6666666666666665e-05,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03DA55</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Aminophylline is a bronchodilator that contains theophylline and ethylenediamine, used to relieve symptoms of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory diseases. It acts by relaxing smooth muscles in the airways and is generally administered in acute exacerbations of asthma or bronchospasm. The combinations formulation is still approved and in clinical use today, particularly in emergency settings.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult individuals following intravenous administration based on available theophylline/aminophylline PK data; no published PK model specific for aminophylline, combinations (ATC R03DA55) found.</p><h4>References</h4><ol><li><p>Angrisani, M, et al., &amp; Rossi, F (1992). Clinical pharmacokinetics of teicoplanin and aminophylline during cotreatment with both medicaments. <i>International journal of clinical pharmacology research</i> 12(4) 165–171. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1297639/\">https://pubmed.ncbi.nlm.nih.gov/1297639</a></p></li><li><p>Miech, RP, &amp; Stein, M (1986). Respiratory pharmacology. Methylxanthines. <i>Clinics in chest medicine</i> 7(3) 331–340. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3533398/\">https://pubmed.ncbi.nlm.nih.gov/3533398</a></p></li><li><p>Dalabih, AR, et al., &amp; Arnold, DH (2014). Aminophylline infusion for status asthmaticus in the pediatric critical care unit setting is independently associated with increased length of stay and time for symptom improvement. <i>Pulmonary pharmacology &amp; therapeutics</i> 27(1) 57–61. DOI:<a href=\"https://doi.org/10.1016/j.pupt.2013.03.001\">10.1016/j.pupt.2013.03.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23523660/\">https://pubmed.ncbi.nlm.nih.gov/23523660</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03DA55;
